Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OCATA THERAPEUTICS -- Ignore unavailable to you. Want to Upgrade?

To: FJB who wrote (14)	11/7/2011 6:22:26 PM
From: Savant	Respond to of 134

Anyone else showing a Minus 256,603,448 shares?? lol

To: FJB who wrote (14)	12/6/2011 11:30:37 AM
From: Savant	Respond to of 134

ACT Announces Two New Appointments to Board of Directors Zohar Loshitzer, CEO of Presbia, and Gregory D. Perry, EVP and CFO of ImmunoGen, Bring Expertise in Commercializing Emerging Medical Technologies, Fundraising and Partnering MARLBOROUGH, Mass., Dec 06, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Gregory D. Perry and Zohar Loshitzer have been appointed to the company's Board of Directors, effective today. Mr. Perry, 51, is executive vice president and chief financial officer (CFO) of ImmunoGen, Inc., a publicly-traded biotechnology firm developing antibody-based anticancer therapeutics. Mr. Loshitzer, 54, is chief executive officer of Presbia, an ophthalmic-device firm, and is principal at Orchard Capital, a private equity firm. "Greg and Zohar are a highly-valued addition to our Board of Directors," said Gary Rabin, chairman and CEO of ACT. "Greg's experience in fundraising and facilitating partnering deals in life sciences and Zohar's background in successfully commercializing emerging technologies in medicine and other fields, as well as his background in finance, will be invaluable for ACT as there are many major milestones in front of us." Prior to joining ImmunoGen in January 2009, Mr. Perry was CFO of Elixer Pharmaceuticals, where he was deeply involved in partnering and fundraising, and before that he was CFO of Domantis, Ltd., a biotechnology company that was acquired by GlaxoSmithKline in 2006. Prior to that, he was senior vice president of finance and CFO of Transkaryotic Therapies, Inc. (TKT) until its acquisition by Shire plc. in 2005, and before that was with PerkinElmer and General Electric. Mr. Loshitzer previously was president, CEO and founder Universal Telecom Services (UTS). He is a co-founder of J2 Global Communications, a Nasdaq-listed company, and co-founder and former managing director of Life Alert Emergency Response, Inc. He currently serves as a managing director of Orchard Telecom, Inc., and as a board member of Environmental Solutions Worldwide, Inc. (ESW), a publicly-traded company engaged through its wholly-owned subsidiaries in the design and development of proprietary catalytic emission conversion, control and support products and technologies for the international transportation, construction and utility markets. He has also served as a board member to MAI Systems Corporation, an AMEX-listed company. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com.

To: FJB who wrote (14)	12/12/2011 10:50:02 AM
From: Savant	1 Recommendation Respond to of 134

ACT Announces Settlements and Filing of Preliminary Proxy Proxy Sets Record Date of December 8, 2011 and Special Meeting Date of January 24, 2012 MARLBOROUGH, Mass., Dec 12, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company has entered into settlement agreements (the "agreements") with 40 holders of certain warrants and debentures. In order to effectuate the terms of the settlement agreements, the company has also filed a preliminary proxy to increase the authorized shares of the company, with a record date of December 8, 2011 and a special meeting date of January 24, 2012. According to the terms of the agreements, ACT will issue approximately 240.5 million shares in total to this group of holders, in exchange for a mutual two-way release of any current and/or future claims. The settlement agreements further provide that the shares will be delivered following the approval of an increase in the company's authorized shares by the company's stockholders. "Announcing these settlements is another significant step in resolving past financial challenges to the company," said Gary Rabin, chairman and CEO of ACT. "I hope that our stockholders understand how important it is to vote 'For' the increase in authorized shares, not only to complete the settlement agreements, but also to ensure that the company can continue to fund its research and development and clinical programs well into the future." ACT's Board of Directors recommends that stockholders vote "For" the increase in authorized shares so that the company may complete the settlements and have additional shares in the future for financing activities to fund operations and retain key personnel. Stockholders are invited to attend the company's Special Meeting, which will be held at the Hyatt Regency in Palm Springs, Calif., on Tuesday, January 24, 2012. Stockholders who have questions or need assistance voting their shares should contact the company's proxy solicitor InvestorCom, Inc. toll-free at (877) 972-0090. Further Information ACT has filed with the Securities and Exchange Commission (the "SEC") a preliminary proxy statement in connection with its proposal to increase its authorized shares. ACT plans to file a definitive proxy statement with the SEC and mail such definitive proxy statement to stockholders of record on the record date for the meeting at which stockholders will be asked to adopt the amendment to the company's certificate of incorporation to increase the company's authorized shares. The company, Mr. Rabin and certain of its directors, executive officers and other members of management may, under SEC rules, be deemed "participants" in the solicitation of proxies from the company's stockholders with respect to the proposed increase in the company's authorized shares. INVESTORS AND STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED INCREASE IN THE COMPANY'S AUTHORIZED SHARES ABOUT THE PROPOSAL AND OTHER IMPORTANT INFORMATION INCLUDING THOSE PERSONS WHO MAY BE DEEMED "PARTICIPANTS" IN THE SOLICITATION. Investors and stockholders may obtain a free copy of the definitive proxy statement when it becomes available, and other documents filed by us with the SEC, including the preliminary proxy statement, at the SEC's web site at sec.gov. Free copies of the definitive proxy statement, when it becomes available, and the Company's other filings with the SEC may also be obtained from the Company by directing a request to Advanced Cell Technology, Inc., 33 Locke Drive, Marlborough, Massachusetts 01752, Attention: Secretary. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com.